Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep1056 | Pituitary - Clinical | ECE2017

Effects of pasireotide treatment on cardio-metabolic risk in patients with Cushing’s disease: an Italian, multicenter study

Albani Adriana , Ferrau Francesco , Messina Erika , Pivonello Rosario , Scaroni Carla , Giordano Carla , Cozzolino Alessia , Zilio Marialuisa , Guarnotta Valentina , Ciresi Alessandro , Iacuaniello Davide , Alibrandi Angela , Colao Annamaria , Cannavo Salvatore

: Patients with Cushing’s disease (CD) have increased cardiovascular risk due to metabolic alterations caused by glucocorticoids excess. Pasireotide, a multireceptor-targeted somatostatin analogue, is a therapeutic option in CD patients in whom surgery is not curative or not feasible. Pasireotide has been shown to be effective in controlling hypercortisolism and to improve metabolic features. Recently, the visceral adiposity index (VAI) has been proposed as a marker of vi...

ea0081p664 | Pituitary and Neuroendocrinology | ECE2022

Impact of COVID-19 lockdown in patients with acromegaly: an Italian multicenter experience

Pirchio Rosa , Simona Auriemma Renata , Cambria Valeria , Gatto Federico , Carosi Giulia , Ragonese Marta , Guarnotta Valentina , Ceccato Filippo , Cozzolino Alessia , Mongioi Laura , Prencipe Nunzia , Nista Federica , Del Sindaco Giulia , Calogero Aldo , Isidori Andrea , Scaroni Carla , Giordano Carla , Ferrau Francesco , Mantovani Giovanna , Ferone Diego , Grottoli Silvia , Iasevoli Felice , Colao Annamaria , Pivonello Rosario

Over the last two years, COVID-19 outbreak and lockdown have exerted a remarkable psychological burden in the general population. Such an impact is supposed to be even worse in acromegaly, known to induce a severe psychological impairment due to its somatic disfigurements and systemic comorbidities. The current observational study aimed at investigating the impact of COVID-19 outbreak and lockdown on psychological health in acromegalic patients as compared to non-acromegalic h...

ea0099ep311 | Adrenal and Cardiovascular Endocrinology | ECE2024

Impact of 10 years of conventional steroids vs dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in treatment-naïve patients with adrenal insufficiency

Guarnotta Valentina , Di Stefano Claudia , Tomasello Laura , Pizzolanti Giuseppe , Arnaldi Giorgio , Giordano Carla

Patients with adrenal insufficiency show higher mortality than in the general population, mainly due to non-physiological daily glucocorticoid overexposure and to inadequate cortisol exposure during stress-related events and illness. The aim of the current study is to compare the impact of 10 years of conventional glucocorticoid (GC) replacement treatment and dual-release hydrocortisone (DR-HC), on anthropometric, metabolic, cardiovascular and bone outcomes in treatment-na&#23...

ea0020p76 | Thyroid | ECE2009

BRAFV600E mutation and timp-1 hyper-expression in classical variants of papillary thyroid carcinoma (PTC)

Bommarito Alessandra , Carissimi Elvira , Richiusa Pierina , Amato Marco Calogero , Russo Leonardo , Zito Giovanni , Pizzolanti Giuseppe , Giordano Carla

BRAFV600E mutation is considered useful in recognizing thyroid cancer aggressiveness or poor prognosis particularly in certain variants of papillary thyroid cancinoma (PTC). A recent meta-analysis identified 12 cancer-versus-non cancer gene candidate as markers of thyroid cancer; among these TIMP-1 (tissue inhibitors of metalloproteinases) was found consistently up-regulated. Our aim was to evaluate BRAFV600E mutation and TIMP-1 expression in 14 PTC class...

ea0020p126 | Thyroid | ECE2009

Antitumor effects of aminobisphosphonates on anaplastic thyroid carcinoma cell lines

Pitrone Maria , Zito Giovanni , Carissimi Elvira , Bommarito Alessandra , Richiusa Pierina , Galluzzo Aldo , Giordano Carla , Pizzolanti Giuseppe , Bullara V

Anaplastic thyropid carcinoma (ATC) is one of the most aggressive endocrine tumors with morphological features of undifferentiated neoplasm. Patients with ATC have a poor prognosis with a mean survival time of 2–6 months. Surgery, radiotherapy and chemotherapy do not improve survival rate. Bisphosphonates, analogs of endogenous pyrophosphates in which a carbon atom replaces the central oxygen atom, are successful agents for the prevention and treatment of postmenopausal o...

ea0016oc2.4 | Thyroid | ECE2008

Identification and enrichment of thyroid stem cells in anaplastic cell lines

Zito Giovanni , Richiusa Pierina , Pizzolanti Giuseppe , Bommarito Alessandra , Carissimi Elvira , Coppola Antonina , Nucera Miriam , Galluzzo Aldo , Giordano Carla

In the last years, a growing body of evidence supports the notion that tumors are organized in a hierarchy of heterogeneous cell populations with different biologic properties and that the capability to sustain tumor formation and growth exclusively resides in a small proportion of tumor cells, termed cancer stem cells (CSC). The existence of CSC was first proven in the context of acute myelogenous leukaemia, and subsequently verified in brain, breast, colon and prostate cance...

ea0016p822 | Thyroid | ECE2008

No association between BRAFV600E and metalloproteinase activity in anaplastic thyroid cell lines

Carissimi Elvira , Bommarito Alessandra , Pizzolanti Giuseppe , Zito Giovanni , Richiusa Pierina , Russo Leonardo , Coppola Antonina , Smeraldi Lucia , Galluzzo Aldo , Giordano Carla

A strong evidence suggests the role of BRAFV600E mutation in determining the aggressiveness of thyroid cancer. To detect how the association of BRAF mutation could influence the aggressiveness of particular subtypes of thyroid tumors, we analysed a possible correlation between BRAFV600E and metalloproteinase (MMPs) activity, as its enhanced production could be an important determinant of tumor invasion. For this purpose, we investigated the activity and t...

ea0056p863 | Pituitary - Clinical | ECE2018

Interim results of a non-interventional, observational study evaluating the long-term safety and efficacy of pasireotide sc in Cushing’s disease

Giordano Carla , Schopohl Jochen , Yuen Kevin C J , Kriemler-Krahn Ulrike , Li Jiang , Maamari Ricardo , Manetti Luca

Introduction: Subcutaneous (sc) pasireotide effectively reduces cortisol levels, improves signs/symptoms and is generally well tolerated in Cushing’s disease (CD) patients, as shown in previous clinical trials. We report interim results from a multicentre, real-world observational study evaluating the long-term safety and efficacy of pasireotide sc in clinical practice in CD patients.Methods: Adults with CD, for whom surgery has failed or is not an ...

ea0037gp.01.03 | Adrenal | ECE2015

Effect of the switch from conventional glucocorticoids to ‘dual release hydrocortisone' in adult patients with primary and secondary adrenal insufficiency: a 6-month multicentre study

Pivonello Rosario , Simeoli Chiara , Isidori Andrea M , Ciresi Alessandro , Savastano Silvia , Auriemma Renata S , Graziadio Chiara , Di Somma Carolina , Giordano Carla , Lenzi Andrea , Colao Annamaria

Adrenal insufficiency (AI) requires life-long glucocorticoid (GC) treatment, which is associated with an increased risk of metabolic syndrome (MS), probably due to cortisol overexposure for multiple drug daily doses, together with an impairment of quality of life (QoL). Moreover treatment compliance (TC) is reported to be suboptimal in AI patients. The current study aimed at investigating the impact of the switch from twice/thrice daily conventional GCs to once daily dual-rele...

ea0037ep1132 | Endocrine tumours | ECE2015

High-dose treatment with somatostatin analogues in neuroendocrine tumours

Modica Roberta , Ramundo Valeria , Marciello Francesca , Marotta Vincenzo , Pizza Genoveffa , Carratu Anna Chiara , Roseto Chiara de Luca di , Buonomano Pasqualina , Giordano Carla , Trimarchi Francesco , Colao Annamaria , Faggiano Antongiulio

Somatostatin analogs (SSA) effectively control symptoms in neuroendocrine tumours (NET), besides showing antiproliferative activity. In progressive or metastatic NET, increasing SSA dose or shortening the dosing interval are common clinical practice, though empirical. Aim of this study is to evaluate efficacy and safety of high-dose SSA treatment in patients with progressive disease under standard SSA dose. Twenty-one patients (median age 56.8 years) with NET of different orig...